SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : NKTR Drug delivery Company
NKTR 53.98-6.5%Nov 13 3:59 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
From: Ian@SI11/2/2006 5:11:53 PM
  Read Replies (1) of 507
 
Up 4-5% AH.

Maybe I'll have to listen to the conf call.

Extract of the forward looking stuff from its PR...

++++++++++++++++++++++++++++++++++++++++++++++++

...
2006 Estimates

-- For the full year 2006, Nektar is increasing its total revenue
estimate range to $190 to $210 million from $170 to $200
million, including an increase in estimated Exubera
manufacturing and royalty revenue to $90 to $100 million from
$70 to $90 million, with most of the Exubera related revenue
being generated by manufacturing sales of Exubera to Pfizer.

-- The company is reducing its GAAP net loss estimates to a range
of $155 to $170 million from $160 to $175 million, and
non-GAAP net loss to $95 to $110 million from $100 to $115
million due to increased margins and R&D expenses which are
lower than planned. Non-GAAP net loss excludes the $17.7
million UAH litigation settlement charge, $22 million of
estimated SFAS 123R non-severance stock based compensation
charges, and approximately $20 million of estimated charges
related to restructuring and severance. See the supplemental
table attached to this press release entitled "Reconciliation
of Non-GAAP Projected Financial Guidance for 2006."

-- The company is not changing its estimates of 2006 cash, cash
equivalents, and short-term investments and investments in
marketable securities which remain at an approximate range of
$415 to $440 at the end of the year.

2007 Preliminary Estimates

The company is providing preliminary financial performance
guidance for the full year 2007 as follows:

-- Total revenue for 2007 in the range of $210 to $250 million,
including Exubera revenue of $110 to $130 million, with most
of the estimated Exubera revenue based on estimated
manufacturing sales of Exubera to Pfizer.

-- GAAP net loss of $110 to $130 million.

-- Non-GAAP net loss of $75 to $95 million. Non-GAAP net loss
excludes approximately $35 million of estimated SFAS 123R
stock based compensation charges. See the supplemental table
attached to this press release entitled "Reconciliation of
Non-GAAP Projected Financial Guidance for 2007."
...
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News